Cargando…

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis

OBJECTIVES: In this paper, we outline and compare pharmaceutical pricing and reimbursement policies for in-patent prescription medicines in three Maghreb countries, Algeria, Morocco, and Tunisia, and explore possible improvements in their pricing and reimbursement systems. METHODS: The evidence info...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahmani, Hajer, Fradi, Ines, Achour, Leila, Toumi, Mondher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443953/
https://www.ncbi.nlm.nih.gov/pubmed/37614557
http://dx.doi.org/10.1080/20016689.2023.2244304
_version_ 1785093949017292800
author Dahmani, Hajer
Fradi, Ines
Achour, Leila
Toumi, Mondher
author_facet Dahmani, Hajer
Fradi, Ines
Achour, Leila
Toumi, Mondher
author_sort Dahmani, Hajer
collection PubMed
description OBJECTIVES: In this paper, we outline and compare pharmaceutical pricing and reimbursement policies for in-patent prescription medicines in three Maghreb countries, Algeria, Morocco, and Tunisia, and explore possible improvements in their pricing and reimbursement systems. METHODS: The evidence informing this study comes from both an extensive literature review and a primary data collection from experts in the three studied countries. KEY FINDINGS: Twenty-six local experts where interviewed Intervieweesincluded ministry officials, representatives of national regulatory authorities, health insurance organizations, pharmaceutical procurement departments and agencies, academics, private pharmaceutical-sector actors, and associations. Results show that External Reference Pricing (ERP) is the dominant pricing method for in-patent medicines in the studied countries. Value-based pricing through Health Technology Assessment (HTA) is a new concept, recently used in Tunisia to help the reimbursement decision of some in-patent medicines but not yet used in the pricing of innovative medicines in the studied countries. Reimbursement decision is mainly based on negotiations set on Internal Reference Pricing (IRP). CONCLUSION: Whereas each country has its specific regulations, there are many similarities in the pricing and reimbursement policies of in-patent medicines in Algeria, Morocco, and Tunisia. The ERP was found to be the dominant method to inform pricing and reimbursement decisions of in-patent medicines. Countries in the region can focus on the development of explicit value assessment systems and minimize their dependence on ERP over the longer-term. In this context, HTA will rely on local assessment of the evidence.
format Online
Article
Text
id pubmed-10443953
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Routledge
record_format MEDLINE/PubMed
spelling pubmed-104439532023-08-23 Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis Dahmani, Hajer Fradi, Ines Achour, Leila Toumi, Mondher J Mark Access Health Policy Review Article OBJECTIVES: In this paper, we outline and compare pharmaceutical pricing and reimbursement policies for in-patent prescription medicines in three Maghreb countries, Algeria, Morocco, and Tunisia, and explore possible improvements in their pricing and reimbursement systems. METHODS: The evidence informing this study comes from both an extensive literature review and a primary data collection from experts in the three studied countries. KEY FINDINGS: Twenty-six local experts where interviewed Intervieweesincluded ministry officials, representatives of national regulatory authorities, health insurance organizations, pharmaceutical procurement departments and agencies, academics, private pharmaceutical-sector actors, and associations. Results show that External Reference Pricing (ERP) is the dominant pricing method for in-patent medicines in the studied countries. Value-based pricing through Health Technology Assessment (HTA) is a new concept, recently used in Tunisia to help the reimbursement decision of some in-patent medicines but not yet used in the pricing of innovative medicines in the studied countries. Reimbursement decision is mainly based on negotiations set on Internal Reference Pricing (IRP). CONCLUSION: Whereas each country has its specific regulations, there are many similarities in the pricing and reimbursement policies of in-patent medicines in Algeria, Morocco, and Tunisia. The ERP was found to be the dominant method to inform pricing and reimbursement decisions of in-patent medicines. Countries in the region can focus on the development of explicit value assessment systems and minimize their dependence on ERP over the longer-term. In this context, HTA will rely on local assessment of the evidence. Routledge 2023-08-20 /pmc/articles/PMC10443953/ /pubmed/37614557 http://dx.doi.org/10.1080/20016689.2023.2244304 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Review Article
Dahmani, Hajer
Fradi, Ines
Achour, Leila
Toumi, Mondher
Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
title Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
title_full Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
title_fullStr Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
title_full_unstemmed Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
title_short Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
title_sort pharmaceutical pricing and reimbursement policies in algeria, morocco, and tunisia: comparative analysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443953/
https://www.ncbi.nlm.nih.gov/pubmed/37614557
http://dx.doi.org/10.1080/20016689.2023.2244304
work_keys_str_mv AT dahmanihajer pharmaceuticalpricingandreimbursementpoliciesinalgeriamoroccoandtunisiacomparativeanalysis
AT fradiines pharmaceuticalpricingandreimbursementpoliciesinalgeriamoroccoandtunisiacomparativeanalysis
AT achourleila pharmaceuticalpricingandreimbursementpoliciesinalgeriamoroccoandtunisiacomparativeanalysis
AT toumimondher pharmaceuticalpricingandreimbursementpoliciesinalgeriamoroccoandtunisiacomparativeanalysis
AT pharmaceuticalpricingandreimbursementpoliciesinalgeriamoroccoandtunisiacomparativeanalysis